March 27, 2025 10:56 AM EDT

Equillium says graft-versus-host drug fails Phase 3, stock dives

Max Gelman

Senior Editor

A penny stock biotech reported that its acute graft-versus-host disease drug failed a late-stage trial, but it still plans to seek accelerated approval.

Equillium …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Equillium says graft-versus-host drug fails Phase 3, stock dives

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Developing: Firings sweep across FDA, gutting leadership and whole offices

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

Federal judge nixes FDA's lab-developed test rule, says it exceeded agency's authority

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Equi­l­li­um says graft-ver­sus-host drug fails Phase 3, stock dives

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Equillium says graft-versus-host drug fails Phase 3, stock dives